Exherin(TM) is a novel tumor vascular targeting agent and is a small peptide molecule that specifically disrupts the blood vessels of cancers through inhibition of the cell adhesion protein
, N-cadherin, that is a critical structural component of some tumor blood vessels.
This cell adhesion protein
is expressed by blood vessel cells but is different from the target of Exherin, Adherex's lead vascular targeting agent.
A number of cardioprotective benefits have been attributed to dietary isoflavones including a reduction in LDL cholesterol, an inhibition of pro-inflammatory cytokines, cell adhesion proteins
and inducible nitric oxide production, potential reduction in the susceptibility of the LDL particle to oxidation, inhibition of platelet aggregation and an improvement in vascular reactivity.
Cadherins are homotypic cell adhesion proteins
that have important roles in tissue morphogenesis and organ development and regulate tumorigenesis by acting as tumor suppressor genes.
Once administered, SF1126 targets specific transmembrane cell adhesion proteins
known as integrins that are expressed in new tumor vasculature and within the tumor compartment.